Clinical & Scientific

After a strong 2025, Viatris unveils a plan for $650M in savings, a 10% workforce cut, and a focus on six new drugs to fuel future innovation.

A newly identified blood biomarker for the drug masitinib could revolutionize how doctors treat ALS, progressive MS, and Alzheimer's disease.

Intellia Therapeutics prepares for a critical March, where it will outline its gene editing future to investors amid safety questions and market pressures.

NorthX Biologics and Demeetra have partnered to offer a streamlined, royalty-free path from gene to GMP, tackling key bottlenecks for biotech startups.

A Korean firm says it can cure 34 diseases using cells from cloned embryos, walking a fine line between a medical breakthrough and a bioethical taboo.

iRegene Therapeutics hits dual milestones, advancing AI-derived cell therapies for Parkinson's in the US and Multiple System Atrophy in China.

With a soaring stock, $300M in new funding, and strong clinical data, Monte Rosa is set to showcase its novel disease-fighting drug platform.

Armed with $320M in new capital, Anteris will showcase its revolutionary biomimetic heart valve to top investors. Can it disrupt a market of giants?

Sōlaria Biō’s new study validates a microbe-based medical food, Bōndia™, offering a novel, science-backed approach to bone loss for millions of women.

With impressive preliminary sales and key pipeline updates, Mirum Pharmaceuticals' upcoming earnings call will focus on its strategy for sustained growth in 2026.

With $3.7M in new capital, Sift Biosciences is developing a novel immunotherapy to awaken the body's memory T cells against hard-to-treat diseases.

A novel drug candidate targeting treatment-resistant kidney disease has begun its long journey through clinical trials, signaling a major strategic push.

As Adagene presents at key conferences, its SAFEbody tech and lead drug muzastotug draw focus amid a strategic push for funding and partnerships.

A new FDA approval allows a lung cancer therapy to be given just once a month, a major shift promising to reduce clinic time and improve quality of life.

A new five-year deal will leverage patient-derived stem cells and AI to revolutionize the hunt for Alzheimer's cures, aiming to bridge a critical gap.

A new partnership aims to manufacture a life-saving gene therapy for NKH, a devastating rare disorder, driven by a family's relentless advocacy.

Bausch Health heads to a key finance conference to address investor concerns over its massive debt, upcoming patent cliffs, and future strategic direction.

As Pasithea Therapeutics heads to a key investor conference, all eyes are on its lead drug, PAS-004, and its potential to treat rare and complex diseases.

A new therapy for a rare brain cancer is one step closer to patients after the FDA accepted tirabrutinib for accelerated review, offering hope where few options exist.

The biotech firm enacts a 1-for-25 stock split to avoid delisting, placing its promising cancer therapy pipeline under a brighter, more critical spotlight.